Myology research highlights
RSS feedEffect of low-level laser therapy on disease evolution in mdx mice
This study evaluated the effects of preventive treatment with low-level laser therapy (LLLT) on the progression of dystrophy in mdx mice. Ten animals were randomly divided into 2 experimental groups treated with superpulsed LLLT (904 nm, 15 mW, 700 Hz, 1 J) or placebo-LLLT at one point overlying the tibialis anterior muscle (bilaterally) 5 times … [Read more]
Tubular aggregate myopathy and congenital miosis associated with mutations in STIM1 and ORAI1
Ca2+ is a major regulatory and signaling molecule in skeletal muscle, therefore the cellular Ca2+ dynamics need to be tightly regulated. Ca2+ stores are refilled through a process called store-operated Ca2+ entry (SOCE). Signaling through the store-operated Ca2+ release-activated Ca2+ (CRAC) channel regulates critical cellular functions, including gene expression, cell growth and differentiation, and Ca2+ … [Read more]
Call 2014 : “Preclinical Research in rare diseases: translational steps in large animals
This 1st call for proposals launched by the French Foundation for rare diseases aims to directly support intermediary key steps towards clinical development for patient.The objective is to support pilot scientific projects at the interface between the in vivo proofs of principle, usually in rodents, and the development of a clinical application in human patients.Submission deadline … [Read more]
Isis Pharmaceuticals’ SMA drug advances in phase 2 trials
Interim results of a phase 2 clinical trial to test multiple doses of the experimental drug ISIS-SMNRx in infants with spinal muscular atrophy (SMA) suggest that the drug is well-tolerated and may prolong ventilator-free survival. The drug is designed to increase the level of full-length, fully functional SMN. In the ongoing phase 2 trial, doses … [Read more]
Bridging integrator 1 (Bin1) deficiency in zebrafish results in centronuclear myopathy
Autosomal recessive centronuclear myopathy (CNM2), caused by mutations in bridging integrator 1 (BIN1), is a mildly progressive neuromuscular disorder characterized by abnormally centralized myonuclei and muscle weakness. BIN1 is important for membrane sensing and remodeling in vitro in different cell types. However, to fully understand the biological roles of BIN1 in vivo and to answer … [Read more]
Facial memory deficits in myotonic dystrophy type 1
In this study, the authors evaluated facial memory ability (FMA) in patients with myotonic dystrophy type 1 (DM1). They also explored the relationship between FMA and neuropsychological data, disease-related factors, and CTG repeat expansion size. Patients with DM1 (n = 33) and healthy subjects (n = 30) were tested with the faces task of the … [Read more]
Prevalence of LGMD2C in the Moroccan population
Autosomal recessive limb-girdle muscular dystrophies (AR-LGMDs) are characterized by clinical and genetic heterogeneity. LGMD type 2C, or γ-sarcoglycanopathy, is the most frequent in North African populations as a result of the founder c.525delT mutation in the SGCG gene. Its epidemiology is poorly known in Morocco, and its prevalence among the Moroccan population has never been … [Read more]
POMK mutation in two siblings with CMD
Congenital muscular dystrophies (CMD) with hypoglycosylation of α-dystroglycan are clinically and genetically heterogeneous disorders that are often associated with brain malformations and eye defects. Presently, 16 proteins are known whose dysfunction impedes glycosylation of α-dystroglycan and leads to secondary dystroglycanopathy. In this study, the authors aimed to identify the cause of CMD with secondary merosin … [Read more]
CMTX5, Arts syndrome and DFN2 form a disease continuum
X-linked Charcot-Marie-Tooth disease type 5 (CMTX5), Arts syndrome, and non-syndromic sensorineural deafness (DFN2) are allelic syndromes, caused by reduced activity of phosphoribosylpyrophosphate synthetase 1 (PRS-I) due to loss-of-function mutations in PRPS1. As only few families have been described, knowledge about the relation between these syndromes, the phenotypic spectrum in patients and female carriers, and the … [Read more]
Childhood myasthenia in the UK
To ascertain the frequency of childhood myasthenia in the UK, the authors specifically aimed to identify the detected incidence of autoimmune myasthenia and the detected prevalence of genetically confirmed congenital myasthenic syndrome (CMS) in children. All children under 18 years of age on 31 December 2009 with a confirmed CMS genetic mutation were identified by … [Read more]